



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07K 7/06, 7/08, A61K 37/02	A1	(11) International Publication Number: WO 90/01037 (43) International Publication Date: 8 February 1990 (08.02.90)
<p>(21) International Application Number: PCT/EP89/00842</p> <p>(22) International Filing Date: 19 July 1989 (19.07.89)</p> <p>(30) Priority data: 8817379.4 21 July 1988 (21.07.88) GB 8906900.9 28 March 1989 (28.03.89) GB</p> <p>(71) Applicant: FARMITALIA CARLO ERBA S.R.L. [IT/IT]; Via Carlo Imbonati, 24, I-20159 Milan (IT).</p> <p>(72) Inventors: de CASTIGLIONE, Roberto ; Via Domenichino, 38, I-20100 Milan (IT). GALANTINO, Mauro ; Via delle Ande, 5, I-Milan (IT). CORRADI, Fabio ; Via Marchiondi, 7, I-Milan (IT). GOZZINI, Luigia ; Viale Stelvio, 27/4, I-Milan (IT). CIOMEI, Marina ; Via Riviera, Massaua, I-27020 Torre D'Isola (IT). MOLINARI, Isabella ; Via Elba, 28, I-Milan (IT).</p>	<p>(74) Agents: KOLB, Helga et al.; Hoffmann, Eitle & Partner, Arabellastrasse 4, D-8000 München 81 (DE).</p> <p>(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FI, FR (European patent), GB (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent), SU.</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: IRREVERSIBLE PEPTIDE LIGANDS FOR BOMBESIN RECEPTORS</p> <p>(57) Abstract</p> <p>Peptides of formula A-B-C-D-Gln-Trp-Ala-Val-X-Y-T-W (either A = H, Boc; AC; one of B and C = pMel, mMel; the other of B and C = valence bond, Gly, Leu-Gly, E-Leu-Gly, Gln-E-Leu-Gly, E-E-Gly with E = Arg(A), arg(A), Lys(A), lys(A), Orn(A), orn(A) or A = H, B = Glp-Arg-Leu-Gly, C = pMel or mMel; and D = valence bond, Asn, Thr; X = Gly, ala; Y = valence bond, His(R₁), his(R₁), Phe, phe, Ser, ser, Ala, ala; T = valence bond, Leu, leu, Phe, phe; W = OH, NH₂NH(CH₂)₄CH₃, NH(CH₂)₂C₆H₅, Met-R₂, Leu-R₂, Ile-R₂, Nle-R₂; R₁ = H, Tos, Dnp, Bzl; R₂ = NH₂, OH, OCH₃, NHNH₂) and their pharmaceutically acceptable salts are irreversible peptide ligands for Bombesin receptors. Their preparation and pharmaceutical compositions containing them are also described.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LJ	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

IRREVERSIBLE PEPTIDE LIGANDS FOR BOMBESIN RECEPTORSDescription

The present invention relates to new biologically active peptides, their pharmaceutically acceptable salts, and the processes for their preparation and application as therapeutic agents.


In this specification symbols and abbreviations are those commonly used in peptide chemistry (see Eur.J. Biochem. (1984) 138, 9-37). Consequently, the three-letter amino acid symbols denote the L configuration of chiral amino acids. D-amino acids are represented by small letters: e.g., ala = D-Ala. Other symbols and abbreviations used are: AA, amino acid; AcOEt, ethylacetate; AcOH, acetic acid; Bzl, benzyl; BBS, bombesin; Boc, t-butyloxycarbonyl; BuOH, butyl alcohol; CCD, counter-current distribution; DCC, N,N'-dicyclohexylcarbodiimide; dec., decomposition; DMAP, 4-dimethylaminopyridine; DMF, dimethylformamide; Dnp, 2,4-dinitrophenyl; ECC, ethylchlorocarbonate; Et₂O, diethylether; Glp, L-pyroglutamic acid; h-GRP (or p-GRP), human (or porcine) gastrin releasing peptide; HCl/AcOH, dry HCl in anhydrous acetic acid; HOBt, 1-hydroxybenzotriazole; i.c.v., intracerebroventricular; MeOH, methyl alcohol; m.p. melting point; mMeI= m-bis(2-chloroethyl)amino-L-phenylalanine; n.d., not determined; NMM, N-methylmorpholine; pMeI= p-bis (2-chloroethyl) amino-L-phenylalanine; HPLC, high performance liquid chromatography;

OSu, N-hydroxysuccinimidyl; TFA, trifluoroacetic acid; THF, tetrahydrofuran; TLC, thin layer chromatography; Tos, p-toluensulphonyl; TsOH, p-toluensulphonic acid; Z, benzyloxycarbonyl.

More particularly, the present invention relates to peptides having bombesin antagonistic activity useful in the therapy of human neoplasms which are depending from peptides of the GRP family.


Other bombesin antagonists have been prepared in the past, but those peptides, however, showed moderate affinity for the BBS receptors. (A. Cowan (1988) TIPS, 9,1-3);

The invention provides peptides of formula (I)



where:

A = H, Boc, Ac



B = pMel, mMel (-Mel--HN-CH-CO-)

C = -(valence bond), Gly, Leu-Gly, E-Leu-Gly, Gln-E-Leu-Gly, E, E-Gly

D = -, Asn, Thr

E = Arg(A), arg(A), Lys(A), lys(A), Orn(A), orn(A)

X = Gly, ala

Y = -, His(R₁), his(R₁), Phe, phe, Ser, ser, Ala, ala

T = -, Leu, leu, Phe, phe

W = OH, NH₂, NH(CH₂)₄CH₃, NH(CH₂)₂C₆H₅, Met-R₂, Leu-R₂, Ile-R₂, Nle-R₂

R₁ = H, Tos, Dnp, Bzl

$R_2 = \text{NH}_2, \text{OH}, \text{OMe}, \text{NH-NH}_2$

B and C can be inverted (B in 3 and C in 2); in this case, when A = H, Gln-Arg-Leu-Gly may become Glp-Arg-Leu-Gly.

Salts of these peptides with pharmaceutically acceptable acids are within the scope of the invention. Such acid addition salts can be derived from a variety of inorganic and organic acids such as sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, nitric, sulfamic, citric, lactic, pyruvic, oxalic, maleic, succinic, tartaric, cinnamic, acetic, trifluoroacetic, benzoic, salicylic, gluconic, ascorbic and related acids.

Bombesin (BBS) is a tetradecapeptide of formula Glp-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂, originally isolated from the skin of a frog. The biological activity resides in the C-terminal part of the molecule. BBS(6-14)nonapeptide is as active as the parent compound. The human counterpart of bombesin is a 27 amino acid peptide known as gastrin-releasing peptide (h-GRP). Bombesin and bombesin-like peptides display a number of biological activities (J.H. Walsh (1983) in "Brain Peptides", D.T. Krieger, M.J. Brownstein and J.B. Martin (eds), Wiley Interscience Publ., pp. 941-960), including autocrine growth-promoting effects on human small cell lung carcinoma (SCLC) (F. Cuttitta et al. (1985) Cancer Survey, 4, 707-727), autocrine and/or paracrine stimulation of human prostatic cancer cell proliferation (M. Rologna et al., Cancer, in press) and modulation of the EGF receptor (I. Zachary and E. Rozengurt (1985) Cancer Surveys, 4, 729-765).

In this case, a bombesin antagonist, by competing with the natural ligand for the receptor(s), would inhibit^{or modify} the triggering of the cascade of events leading to abnormal cell proliferation.

The alkylating bombesin analogues of the formula I are bombesin receptor antagonists and can, therefore, find application in the therapy of human neoplasm which are modulated in their growth and progression by peptides of the GRP family, either directly or in concert with other growth factors.

In addition, these alkylating analogues can be used in the management of the clinical symptoms associated with these diseases and due to hypersecretion of GRP-like peptides.

The compounds of the invention can be administered by the usual routes, for example, parenterally, e.g. by intravenous injection or infusion, or by intramuscular, subcutaneous, intracavity and intranasal administration.

The dosage depends on the age, weight and condition of the patient and on the administration route.

On the basis of the "in vitro" and "in vivo" data in mice it can be estimated that the therapeutic doses in humans will be in the range 10 ng/kg - 10 mg/kg, once to 6 times daily.

The invention also provides

pharmaceutical compositions containing a compound of formula (I) as the active substance, in association with one or more pharmaceutically acceptable excipients.

The pharmaceutical compositions of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.

For instance, solutions for intravenous injection or infusion may contain as carrier, for example, sterile water or, preferably, they may be in the form of sterile aqueous isotonic saline solutions.

Suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride.

Furthermore, according to the invention there is provided a method of treating neuroendocrine neoplasms, such as small cell

lung carcinoma and prostatic carcinoma or the clinical symptoms associated with these diseases in a patient in need of it, comprising administering to the said patient a composition of the invention.

Chemistry

The synthesis of the peptides of the invention may be accomplished by classical solution methods. The synthesis consists essentially of appropriate successive condensations of protected amino acids or peptides. The condensations are carried out so that the resulting peptides have the desired sequence of amino acid residues.

The amino acids and peptides, which can be condensed according to methods known in peptide chemistry, have the amino and carboxyl groups, not involved in peptide bond formation, blocked by suitable protecting groups capable of being removed by acid or alkali treatment or by hydrogenolysis.

For the protection of the amino group the following protective groups may, for example, be employed: benzyloxycarbonyl, t-butoxycarbonyl, trityl, formyl, trifluoracetyl, o-nitrophenylsulphenyl, 4-methyloxybenzyloxycarbonyl, 9-fluorenylmethoxycarbonyl, 3,5-dimethoxy- α - α' -dimethylbenzyloxycarbonyl or methylsulphonyl-ethoxycarbonyl.

For the protection of the carboxyl group the following protective groups may, for example, be employed: methyl, ethyl, t-butyl, benzyl, p-nitrobenzyl or fluorenylmethyl, amide, hydrazide, t-butoxycarbonyl hydrazide or benzyloxycarbonyl hydrazide.

The hydroxy functions of hydroxy amino acids and the imino function of histidine may be protected by suitable protecting groups (throughout all the synthesis or only during a few steps) or may be unprotected. For the protection of the hydroxy function the following protective groups may, for example, be employed; t-butyl,

benzyl, acetyl. For the protection of the imidazole imino function the following groups may, for example, be used: 2,4-dinitrophenyl, tosyl, benzyl. De-protecting reactions are carried out according to methods known per se in peptide chemistry.

The condensation between an amino group of one molecule and a carboxyl group of another molecule to form the peptidic linkage may be carried out through an activated acyl-derivative such as a mixed anhydride, an azide or an activated ester, or by direct condensation between a free amino group and a free carboxyl group, in the presence of a condensing agent such as dicyclohexylcarbodiimide, alone or together with a racemization preventing agent, such as N-hydroxysuccinimide or 1-hydroxybenzotriazole, or together with an activating agent such as 4-dimethylamino-pyridine. The condensation may be carried out in a solvent such as dimethylformamide, dimethylacetamide, pyridine, acetonitrile, tetrahydrofuran or N-methyl-2-pyrrolidone.

The reaction temperature may be from -30°C to room temperature. The reaction time is generally from 1 to 120 hours.

The scheme of synthesis, the protecting groups and condensing agents are selected so as to avoid the risk of racemization.

R_f values are determined on pre-coated plates of silica gel 60 F₂₅₄ (Merck), layer thickness 0.25 mm, length 20 cm, using the following development systems:

System A: ethyl acetate/benzene/acetic acid/water
= 500/500/100/50 by volume (upper phase)

System B: ethyl acetate/benzene/acetic acid/water
= 500/500/200/75 by volume (upper phase)

System C: n-butanol/acetic acid/water = 600/150/150
by volume

System D: chloroform/methanol/ NH_4OH 30% = 488/338
150 by volume

System E: chloroform/methanol = 90/10 by volume

System F: toluene/ethylacetate/acetic acid/water =
100/100/20/10 by volume

TLC analyses are carried out at a temperature ranging from 18°C to 25°C: the R_f values can therefore change $\pm 5\%$.

High performance liquid chromatography (HPLC) was carried out using a Hewlett-Packard 1084B apparatus equipped with a UV detector operating at 210 nm. The peptides are separated on a 4 x 250 mm Lichrosorb RP 18 5μ column. The following solvents are used:

A) 0.02 M KH_2PO_4 adjusted to pH 3.5 with 3% H_3PO_4 / CH_3CN = 9/1 by volume

B) 0.02 M KH_2PO_4 adjusted to pH 3.5 with 3% H_3PO_4 / CH_3CN = 3/7 by volume.

The elution is programmed with a linear gradient from 60% to 90% B over a period of 20 min (System A) or from 30 to 70% B over a period of 15 min (System B), and then isocratically for 15 min, with a flow rate of 1 ml/min.

The peptides are characterized by their retention time (RT).

Amino acid analysis have been carried out on acid hydrolysates (either at 110°C for 22 h in 6 N HCl + 0.1% phenol or at 100°C for 16 h in 3 N mercaptoethansulfonic acid, both under N_2). Only

natural amino acid residues have been determined. Due to partial decomposition in normal hydrolysis conditions, Trp has been determined only in hydrolysates with the sulfonic acid.

Biology

The binding affinity of the compounds of the present invention for the bombesin receptors has been determined on mouse Swiss 3T3 fibroblasts (I. Zachary and E. Rozengurt (1985) Proc. Natl. Acad. Sci. USA, 82, 7616-7620) (Table 1).

The effect on ^{mitogenesis} has been determined in quiescent and confluent Swiss 3T3 cells maintained in serum free medium (A.N. Corps et al (1985) Biochem J. 231, 781-785). In a first set of experiments, analogues are given alone or in combination with bombesin. In a second set of experiments, cells are pre-treated with the alkylating peptides, washed, left at 37°C for 24 hours and then challenged with bombesin. In both cases, DNA synthesis has been evaluated as [H^3]thymidine incorporation (Table 2).

Mitogenic effect of bombesin and its analogues have been also evaluated as activation of the protein-tyrosin kinase that phosphorylates a 115 KD protein (p115) associated with the bombesin receptor complex (D. Cirillo et al. (1986) Mol. Cell. Biol. 6, 4641-4649) (Table 3).

In addition, exposure to these peptides in the 0.1-50 μ M range was associated with significant reduction in the growth of SCLC cell lines (such as NCI-H345, NCI-N592, NCI-H128), as well as of prostatic carcinoma cell lines (such as DU145 and PC3).

Parenteral administration of these peptides at doses ranging between 10 ng/kg - 10 mg/kg to nude mice was associated with significant growth reduction of the above mentioned transplanted human SCLC and prostatic carcinoma cell lines.

Peripheral and central effects have been evaluated in the rat, respectively "in vitro", as urinary bladder contraction (M. Broccardo et al. (1975) Br. J. Pharmac., 55, 221-227) and "in vivo" by i.c.v. administration, as grooming behaviour (A.Cowan et al. (1985) Life Sciences, 37, 135 - 145), both in the absence and in the presence of bombesin.

EXAMPLE 1

Boc-pMel-Gln-Trp-Ala-Val-Gly-OH (III)

Step 1 Boc-pMel-OH (I)

0.684 g (1.85 mmol) of H-pMel-OEt.HCl (F.Bergel and J.A. Stock (1954) J.Chem. Soc. 2409-2417) and 0.485 g (2.2 mmol) of (Boc)₂O were dissolved in 40 ml of water and 8 ml of t-BuOH. The solution was adjusted to pH 10 with 1N NaOH, stirred for 15 min, then 40 ml of water and 110 ml of MeOH were added, and the pH brought to 13.5 with 1 NaOH. The reaction mixture was stirred for 1 hr at room temperature, then brought to pH 8.5 with 1N HCl and concentrated in vacuo. The aqueous solution was washed with n-hexane (4x30 ml), then cooled to -5°C, acidified to pH 2 with 1N HCl under stirring, and extracted with cooled AcOEt (4 x 30 ml). The organic layers were pooled, washed to neutrality with saturated solution of NaCl,

dried over anhydrous Na_2SO_4 , filtered and evaporated in vacuo. The residue was dissolved in a mixture of $\text{CH}_2\text{Cl}_2/\text{AcOH}$ 99/1 and purified by flash chromatography on silica gel eluting with the same solvent mixture. 0.7 g (77.8% yield) of product I were obtained as an oil: R_{FA} 0.70.

Step 2 Boc-pMel-Gln-Trp-Ala-Val-Gly-OBzl (II)

0.6 g of Boc-pMel-OH (I) (1.48 mmol) were dissolved in 10 ml of anhydrous THF. The solution was cooled to -20°C , and 0.16 ml (1.48 mmol) of NMM and 0.15 ml (1.48 mmol) of ECC were successively added. After stirring at this temperature for 2 min, a cold solution of 1.02 g (1.48 mmol) of H-Gln-Trp-Ala-Val-Gly-OBzl . HCl (our UK patent application n°8808768.9), and 0.16 ml (1.48 mmol) of NMM in 10 ml of anhydrous DMF, was added. The reaction mixture was stirred for 2 h at -10° to -15°C , then filtered and evaporated in vacuo.

The residue was dissolved in 20 ml of DMF and poured dropwise into 40 ml of a 10% solution of citric acid at 5°C . The mixture was stirred for 1 h at a temperature below 10°C , then filtered and washed with water to neutrality. 1.4 g (91.5% yield) of product II were obtained: R_{FA} 0.48

Step 3 Boc-pMel-Gln-Trp-Ala-Val-Gly-OH (III)

0.44 g of 10% Pd/C and 24 ml of a pre-warmed solution made from 1.2 ml of HCOOH , 3.3 ml of NMM and 100 ml of MeOH, were added to a

solution of 1.2 g (1.16 mmol) of Boc-pMel-Gln-Trp-Ala-Val-Gly-OBzl (II) in 24 ml of anhydrous DMF. The reaction mixture was stirred for 15 min at 40°C, then cooled to room temperature, filtered and evaporated in vacuo. The residue was dissolved in DMF and precipitated with AcOEt, giving 1.1 g of crude product. This was purified by counter current distribution in the solvent system: water/DMF/n-BuOH/AcOEt = 40/3/20/80. Fractions containing the pure product were pooled and evaporated in vacuo. The residue was ground in DMF, MeOH and AcOEt, giving 0.680 g (63% yield) of product III: R_{FD} 0.54; RT_A 8.4; AA ratios; Glu 0.93 (1), Gly 0.99 (1), Ala 0.99 (1), Val 1 (Trp and pMel n.d.).

Example 2

Boc-pMel-Gln-Trp-Ala-Val-Gly-His(Dnp)-Leu-Met-NH₂ (IV)

To a solution of 0.330 g (0.35 mmol) of Boc-pMel-Gln-Trp-Ala-Val-Gly-OH (III) in 3 ml of anhydrous DMF, 0.053 g (0.39 mmol) of anhydrous HOBt, 0.081 g (0.39 mmol) of DCC, 0.235 g (0.39 mmol) of H-His(Dnp)-Leu-Met-NH₂ · HCl (F. Angelucci and R. de Castiglione (1975) *Experientia*, 507-508) and 0.043 ml (0.39 mmol) of NMM were successively added. The reaction mixture was stirred at 0°C for 1 h and at room temperature for 30 h, then it was filtered and evaporated in vacuo. The residue was dissolved in 3 ml of anhydrous DMF, poured dropwise into 30 ml of an aqueous solution of 6 g NaCl and 3 g citric acid at a temperature below 10°C. After stirring for 1 h at a temperature < 10°C, the suspension was filtered and the

product was washed to neutrality. The crude material was evaporated twice from 10 ml of anhydrous DMF, then dissolved in 3 ml of anhydrous DMF and poured dropwise into 30 ml of an aqueous solution of 1.5 g NaHCO_3 and 6g NaCl at a temperature below 10°C . The mixture was stirred for 1 h, then filtered and washed with water to neutrality, giving 0.5 g (95.6% yield) of product IV: $R_{\text{FD}} = 0.84$; RT_λ 21.2; AA ratios: Trp 0.97 (1), Glu 1.00 (1), Gly 1, Ala 1.00 (1), Val 1.00 (1), Met 1.10 (1), Leu 1.04 (1) (pMel and His(Dnp) n.d.).

Example 3

H-pMel-Gln-Trp-Ala-Val-Gly-His(Dnp)-Leu-Met- NH_2 . HCl (V)

0.100 g (0.067 mmol) of Boc-pMel-Gln-Trp-Ala-Val-Gly-His(Dnp)-Leu-Met- NH_2 (IV) were made to react with 1 ml of 1.33N HCl/AcOH containing, 0.2 ml of 2-mercaptoethanol and 0.1 ml of anisole. The reaction mixture was stirred for 30 min at room temperature, then evaporated in vacuo. The residue was ground with Et_2O , giving 0.080 g (83.5% yield) of product V: $R_{\text{FC}} = 0.57$; RT_λ 9.3; AA ratios: Glu 0.99 (1), Gly 0.98 (1), Ala 1.04 (1), Val 1.10 (1), Met 0.82 (1), Leu 0.81 (1) (Trp, pMel and His(Dnp) n.d.).

Example 4**Boc-pMel-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂ (VI)**

0.4 g (0.27 mmol) of Boc-pMel-Gln-Trp-Ala-Val-Gly-His(Dnp)-Leu-Met-NH₂ (IV) were dissolved in 400 ml of anhydrous DMF, then 5.36 ml of 0.1 M KH₂PO₄ (brought to pH 8.1 with 1N KOH) and 20 ml of 2-mercaptoethanol were added. The reaction mixture was stirred for 2 h at room temperature, then concentrated in vacuo. The residue was purified by counter-current distribution in the solvent system: water/n-BuOH/AcOH = 40/35/1. Fractions containing the pure product were pooled and evaporated in vacuo, giving 0.35 g (theoretical yield) of product VI: R_{fc} 0.63; R_{fd} 0.82; RT_A 14.2; AA ratios: Glu 1, Gly 1.00 (1); Ala 1.04 (1), Val 1.04 (1); Met 0.94 (1), Leu 1.02 (1), His 0.95 (1), Trp 0.88 (1) (pMel n.d.).

Example 5**H-pMel-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂ . 2 HCl (VII)**

0.1 g (0.075 mmol) of Boc-pMel-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂ (VI) were deblocked as described in example 3, obtaining 0.089 g (91% yield) of product VII: R_{fc} 0.45; RT_B 11.3; AA ratios: Glu 1.06 (1), Gly 1.00 (1), Ala 0.99 (1), Val 1, Met 0.94 (1), Leu 0.96 (1), His 0.94 (1) (Trp and pMel n.d.).

Example 6**Boc-pMel-Gln-Trp-Ala-Val-Gly-phe-Leu-Met-NH₂ (VIII)**

0.15 g (0.16 mmol) of Boc-pMel-Gln-Trp-Ala-Val-Gly-OH (III) were dissolved in 12 ml of anhydrous DMF, and 0.023 g (0.169 mmol) of anhydrous HOBt were added. To the solution, cooled at 0°C, 0.041 g (0.177 mmol) of DCC, 0.085 g (0.192 mmol) of H-phe-Leu-Met-NH₂ . HCl (our UK Patent Appl. n° 8808768.9, example 1 - step 14) and 0.022 ml of NMM (0.192 mmol) were added successively.

After stirring for 15 min at 0°C, 0.002 g (0.016 mmol) of DMAP were added. The reaction mixture was stirred for 1 h at 0°C and overnight at room temperature, then filtered and evaporated in vacuo. The residue was dissolved in 3 ml of anhydrous DMF and poured dropwise into 30 ml of an aqueous solution of 3 g citric acid and 6 g NaCl, at a temperature below 10°C. After stirring for 1 h, the solid was filtered and washed with water to neutrality. The product was then dissolved in 10 ml of anhydrous DMF and evaporated in vacuo. The residue was ground with Et₂O, giving 0.190 g (88.8% yield) of crude compound VIII. A sample was purified by reverse phase semi-preparative HPLC using a linear gradient system of 0.05% TFA (A) and 0.05% TFA/CH₃CN= 3/7 (B), from 70% to 90% B: R_{fc} 0.85; RT_A 18.4; AA ratios: Glu 0.90 (1); Gly 1.14 (1), Ala 1.02 (1), Val 0.99 (1); Met 0.94 (1), Leu 1.08 (1), phe 0.96 (1), Trp 0.96 (1) (pMel n.d.).

Example 7**Boc-mMel-Gln-Trp-Ala-Val-Gly-OH (IX)**

The title compound was obtained as described in Example 1, starting from Boc-mMel-OH, obtained in turn from H-mMel-OH (H.F. Gram et al. (1963) J. Med. Chem., 6, 85-87): R_{FD} 0.56; RT_A 8.5; AA ratios: Glu 0.93 (1), Gly 0.95 (1), Ala 0.95 (1), Val 1 (Trp and mMel n.d.).

Example 8**Boc-mMel-Leu-Gly-Thr-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂ (XIV)**Step 1 Boc-Leu-Gly-OBzl (X)

2.33 ml (20.7 mmol) of NMM and 2.91 ml (20.7 mmol) of isobutylchlorocarbonate were successively added to a solution, cooled at -25°C, of 4.8 g (20.7 mmol) of Boc-Leu-OH in 70 ml of anhydrous THF. After stirring the reaction mixture for 3 min at ca. -12°C, a cold solution of 6.98 g (20.7 mmol) of H-Gly-OBzl.TsOH and 2.33 ml (20.7 mmol) of NMM in 50 ml of anhydrous DMF was added. The reaction mixture was stirred for 45 min at ca. -12°C and for 90 min at 0°C, then filtered and evaporated in vacuo. The residue was dissolved in AcOEt and washed several times successively with a 10% aqueous solution of citric acid, brine, a 5% solution of NaHCO₃ and brine again. The organic layer was dried over anhydrous Na₂SO₄ and the solvent removed in vacuo, obtaining 7.8 g (100 % yield) of compound X as an oil: R_{FD} 0.83; RT_A 13.6.

Step 2 H-Leu-Gly-OBzl . HCl (XI)

7.4 g (19.6 mmol) of Boc-Leu-Gly-OBzl (X) was deblocked as described in Example 3. The oily residue was ground several times with petroleum ether, obtaining 3.94 g (63.8% yield) of compound XI: R_{F} 0.59.

Step 3 Boc-mMel-Leu-Gly-OBzl (XII)

5.7 g (12.51 mmol) of Boc-mMel-OH and 3.94 g (12.51 mmol) of H-Leu-Gly-OBzl . HCl (XI) were condensed as described in Example 1 - step 2. The residue was dissolved in AcOEt and washed several times successively with a 10% citric acid solution, brine, a 5% NaHCO_3 solution and brine again. The organic layer was dried over anhydrous Na_2SO_4 and the solvent removed in vacuo. The residue was purified by flash chromatography on silica gel, eluting with AcOEt/ Et_2O =1/7. 6.25 g (75% yield) of product XII were obtained as a foam : R_{F} 0.80.

Step 4 Boc-mMel-Leu-Gly-OH (XIII)

6.0 g (9.0 mmol) of Boc-mMel-Leu-Gly-OBzl (XII) were treated as described in Example 1 - step 3. The residue was ground with AcOEt/ Et_2O /petroleum ether, giving 4.3 g (83% yield) of compound XIII: R_{F} 0.43.

Step 5 Boc-mMel-Leu-Gly-Thr-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂
(XIV)

0.092 g (0.16 mmol) of Boc-mMel-Leu-Gly-OH (XIII) and 0.105 g (0.16 mmol) of H-Thr-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂.HCl (our UK Patent Appl. n° 8808768.9, Example 4) were condensed as described in Example 2. After evaporation of the solvent, the residue was dissolved in 10 ml of DMF, poured dropwise in 100 ml of a 10% solution of citric acid, stirred for 15 min, then filtered and washed to neutrality. The crude product was dissolved in 30 ml of DMF and evaporated in vacuo. The residue was ground with DMF/MeOH/AcOEt/Et₂O, giving 0.17 g (72.7% yield) of crude compound XIV. A sample was purified by semi-preparative HPLC as described in Example 6: R_{fc} 0.84; RT_A 16.5; AA ratios: Thr 0.94 (1), Glu 1.06 (1), Gly 2.12 (2), Ala 0.94 (1), Val 0.94 (1), Met 1.00 (1), Leu 2, Trp 0.87 (1) (mMel n.d.).

In an analogous manner the following peptides have also been synthesized.

XV H-pMel-Gln-Trp-Ala-Val-Gly-phe-Leu-Met-NH₂ . HCl
R_{fc} 0.72; RT_A 9.6.

XVI Boc-mMel-Gln-Trp-Ala-Val-Gly-His(Dnp)-Leu-Met-NH₂
R_{fc} 0.86; RT_A 21.5; AA ratios: Glu 1, Gly 0.99 (1), Ala 1.03 (1), Val 0.99 (1), Met 1.03 (1), Leu 1.04 (1), Trp 1.05 (1) (mMel and His(Dnp) n.d.)

- XVII H-mMel-Gln-Trp-Ala-Val-Gly-His(Dnp)-Leu-Met-NH₂ . HCl
R_{fc} 0.74; RT_A 9.4; AA ratios: Glu 0.99 (1), Gly 1.04 (1),
Ala 1.02 (1), Val 1, Met 0.96 (1), Leu 0.96 (1) (His(Dnp)
Trp and mMel n.d.)
- XVIII Boc-mMel-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂.CF₃COOH
R_{fc} 0.55; R_{fd} 0.80; RT_A 14.4; AA ratios: Glu 1, Gly 0.99
(1), Ala 0.99 (1), Val 1.06 (1), Met 1.05 (1), Leu 0.97
(1), His 0.90 (1), Trp 1.03 (1) (mMel n.d.)
- XIX H-mMel-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂ . 2 HCl
R_{fc} 0.44; RT_B 11.3; AA ratios: Glu 1.00 (1), Gly 1.00
(1), Ala 1.05 (1), Val 1, Met 0.91 (1), Leu 0.89 (1), His
0.99 (1), (mMel and Trp n.d.)
- XX Boc-mMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂
R_{fc} 0.74; RT_A 15.4; AA ratios: Glu 1.03 (1), Gly 1, Ala
1.04 (1), Val 0.96 (1), Met 0.93 (1), Leu 1.02 (1), Trp
0.94 (1) (mMel n.d.)
- XXI H-mMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂ . HCl
R_{fc} 0.65; RT_A 5.7
- XXII H-mMel-Leu-Gly-Thr-Gln-Trp-Ala-Val-Gly-Leu-NH₂ .HCl
R_{fc} 0.52; RT_A 6.6

- XXIII H-pMel-Leu-Gly-Thr-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂ .HCl
- XXIV H-pMel-Gln-Trp-Ala-Val-ala-His-Leu-Met-NH₂ .2HCl
- XXV H-pMel-Asn-Gln-Trp-Ala-Val-Gly-Leu-Nle-NH₂ .HCl
- XXVI H-pMel-Asn-Gln-Trp-Ala-Val-Gly-Leu-NH(CH₂)₄CH₃ .HCl
- XXVII H-pMel-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂ .HCl
- XXVIII H-pMel-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂ .2HCl
- XXIX H-pMel-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-ala-Leu-Nle-NH₂ .HCl
- XXX H-pMel-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-ala-Leu-NH(CH₂)₂C₆H₅ .HCl
- XXXI H-Glp-Arg-Leu-Gly-pMel-Asn-Gln-Trp-Ala-Val-Gly-Leu-Nle-NH₂ .HCl
- XXXII H-Leu-Gly-pMel-Gln-Trp-Ala-Val-Gly-phe-Leu-Nle-NH₂ .HCl
- XXXIII H-Leu-Gly-pMel-Gln-Trp-Ala-Val-Gly-ala-Leu-Nle-NH₂ .HCl
- XXXIV H-pMel-Asn-Gln-Trp-Ala-Val-Gly-Leu-Leu-NH-NH₂ .HCl
- XXXV Boc-pMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂
Rf_C 0.86; RT_A 15.3; AA ratios: Glu 1.02(1), Gly 1.07(1), Ala 1.10(1), Val 1, Met 0.92(1), Leu 0.98(1) (Trp and pMel n.d.)
- XXXVI H-pMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂ .HCl
Rf_C 0.57; RT_B 16.8; AA ratios: Glu 1.08(1), Gly 1.01(1), Ala 0.98(1), Val 1, Met 0.90(1), Leu 0.94(1) (Trp and pMel n.d.)
- XXXVII Boc-Lys(Boc)-Gly-pMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂
Rf_C 0.73; RT_A 18.7; AA ratios: Glu 1.07(1), Gly 2.02(2), Ala 1.18(1), Val 1, Met 0.88(1), Leu 0.95(1), Lys 1.08(1) (Trp and pMel n.d.)
- XXXVIII H-Lys-Gly-pMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂ .2CF₃COOH
Rf_E 0.71; RT_B 15.4; AA ratios: Glu 0.99(1), Gly 2.02(2), Ala 1.00(1), Val 1, Met 0.88(1); Leu 0.91(1), Lys 1.15(1), Trp 0.91(1) (pMel n.d.)

- XXXIX Ac-Lys(Boc)-Gly-pMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂
 Rf_C 0.77; RT_A 11.9; AA ratios: Glu 1.05(1), Gly 1.97(2), Ala 0.98(1), Val 1, Met 0.89(1), Leu 0.92(1), Lys 0.92(1), Trp 0.88(1)(pMel n.d.)
- XL Ac-Lys-Gly-pMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂.CF₃COOH
 Rf_D 0.78; RT_B 16.2, AA ratios: Glu 1; Gly 2.11(2); Ala 0.99(1); Val 0.89(1); Met 0.91(1); Leu 0.92(1); Lys 1.10(1)(Trp and pMel n.d.)
- XLI Boc-pMel-Leu-Gly-Thr-Gln-Trp-Ala-Val-His(Dnp)-Leu-NH(CH₂)₄CH₃
 Rf_C 0.88; RT_A 24.2: AA ratios: Thr 1.04(1), Glu 0.96(1), Gly 2, Ala 1.03(1), Val 0.95(1), Leu 1.92(2) (His(Dnp), Trp and pMel n.d.)
- XLII H-pMel-Leu-Gly-Thr-Gln-Trp-Ala-Val-His(Dnp)-Leu-NH(CH₂)₄CH₃.HCl
 Rf_C 0.50: RT_A 18.7: AA ratios: Thr 0.92(1). Glu 0.97(1), Gly 2.04(2), Ala 1.04(1), Val 1, Leu 1.88(2) (His(Dnp), Trp and pMel n.d.)
- XLIII Boc-pMel-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-ala-Leu-Nle-NH₂.CF₃COOH
 RT_A 18.4
- XLIV H-pMel-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-ala-Leu-Nle-NH₂.2CF₃COOH

TABLE 1

BINDING AFFINITY OF BOMBESIN
ALKYLATING ANALOGUES ON MOUSE SWISS 3T3 FIBROBLASTS

COMPOUND	ID ₅₀ (nM)
III	12,000 ⁺ ₄₀₀
IX	8,200 ⁺ ₆₈₀
VII	60 ⁺ ₂₀
V	680 ⁺ ₁₅₀
XIX	95 ⁺ ₈
XVII	148 ⁺ ₂₇
VI	48 ⁺ ₂
IV	1,170 ⁺ ₄₀₀
XVIII	40 ⁺ ₁₂
XVI	390 ⁺ ₁₆₀
XX	60.1 ⁺ _{3.3}
XIV	445 ⁺ ₆₀

Reference peptides:

BBS	12.6 ⁺ _{3.8}
Spantide	11,100
[pro ²]Spantide	14,000
[Leu ¹³ ψ(CH ₂ -NH)Leu ¹⁴]BBS	214 ⁺ ₃₀

TABLE 2

[H³]THYMIDINE INCORPORATION IN MOUSE SWISS 3T3 FIBROBLASTS

COMPOUND	FOLD INCREASE OVER BASAL VALUE				% INHIBITION IN THE PRESENCE OF			
					25nM BBS			
					A		B	
	5nM	50nM	500nM	5000nM	500nM	5000nM	500nM	5000nM
III	-	-	1.2	1.3	0	64 \pm 10	27 \pm 14	39 \pm 7
IX	-	-	1	1	0	57 \pm 13	17 \pm 4	22 \pm 3
VII	2.1	4.7	4.3	4.8	6 \pm 2	17 \pm 4	57 \pm 14	61 \pm 9
V	1	1	1.4	1.8	26 \pm 8	44 \pm 12	87 \pm 9	83 \pm 6
XIX	1	4.1	4.3	4.4	19 \pm 7	9 \pm 5	54 \pm 1	62 \pm 6
XVII	1	2.9	4.2	3.9	6 \pm 3	20 \pm 7	58 \pm 13	62 \pm 1
VI	4.1	8.0	7.0	6.6	3 \pm 2	20 \pm 3	21 \pm 3	34 \pm 5
IV	1	1	1.7	2.3	59 \pm 3	67 \pm 3	81	73
XVIII	5.4	7.0	7.3	5.4	4 \pm 2	3 \pm 1	3 \pm 2	14 \pm 3
XVI	1.2	1.6	3.1	3.9	17 \pm 2	41 \pm 1	47 \pm 10	37 \pm 7
VIII	-	1.1	1.2	1.2	28 \pm 6	37 \pm 4	56 \pm 3	77 \pm 11
XX	-	1.0	1.5	1.2	39 \pm 1	68 \pm 8	0	35 \pm 3
XIV	-	1.2	1.3	1.2	6 \pm 2	14 \pm 2	0	32 \pm 8
Reference peptides:								
BBS	3.0 \pm 1							
[Leu ¹³ ψ(CH ₂ -NH)Leu ¹⁴]BBS		1.0	1.0		29 \pm 10	56 \pm 4	0	0

A= analogues are given in combination with BBS

B= cells are pre-treated with analogues, washed, left at 37°C for 24 h and then challenged with BBS

TABLE 3


PHOSPHORYLATION OF THE p115 PROTEIN ASSOCIATED
WITH THE BOMBESIN RECEPTOR

COMPOUND	MINIMAL ACTIVE DOSE (nM)
III	> 10000
VII	1
V	100
XIX	4
XVII	4
VI	1
IV	50
XVIII	10
XVI	40
XX	> 500
XIV	> 1000

Reference peptides:


BBS	3
Spantide	> 10000

From the above tables, it is evident that when the alkylating moiety was introduced into an agonist structure (compounds VI, VII, XVIII, XIX) the resulting alkylating analogs increased thymidine incorporation when given alone, and were weak antagonists when given together with BBS but potent antagonists when given 24 hrs before the BBS addition. When the alkylating moiety was introduced into BBS analogues which are "per se" inactive (compounds III and IV) or weak antagonists (compounds IV, V, VIII, XIV, XVI, XVII and XX) the resulting alkylating compounds did not increase incorporation of thymidine and they usually behaved as potent antagonists either when given contemporaneously with BBS or when given 24 hrs after BBS treatment.



CLAIMS:

i. A peptide of the formula I:



wherein

either

A represents a hydrogen atom, a Boc or an acetyl group,
one of B and C represents a pMel or mMel residue,
and

the other of B and C represents a valence bond
or a Gly, Leu-Gly, E-Leu-Gly or Gln-E-Leu-
-Gly, E, E-Gly residue with E = Arg (A), arg (A),

Lys (A), lys (A), Orn (A) and orn (A), or

A represents a hydrogen atom,

B represents a Glp-Arg-Leu-Gly residue, and

C represents a pMel or mMel residue,

and

D represents a valence bond or an Asn or Thr
residue,

X represents a Gly or ala residue,

Y represents a valence bond or a His(R₁),
his(R₁), Phe, phe, Ser, ser, Ala or ala residue,

T represents a valence bond or a Leu, leu, Phe
or phe residue, OH,

W represents an/amino, pentylamino or phenethyl-
amino group or Met-R₂, Leu-R₂, Ile-R₂ or
Nle-R₂ residue,

R₁ represents a hydrogen atom or a Tos, Dnp or
Bzl group, and

R₂ represents an amino, hydroxy, methoxy or
hydrazino group;

or a pharmaceutically acceptable salt of such a peptide.

2. Any one of the following peptides:

Boc-pMel-Gln-Trp-Ala-Val-Gly-OH

Boc-mMel-Gln-Trp-Ala-Val-Gly-OH

Boc-pMel-Gln-Trp-Ala-Val-Gly-His(Dnp)-Leu-Met-NH₂H-pMel-Gln-Trp-Ala-Val-Gly-His(Dnp)-Leu-Met-NH₂Boc-pMel-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂H-pMel-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂Boc-pMel-Gln-Trp-Ala-Val-Gly-phe-Leu-Met-NH₂Boc-mMel-Leu-Gly-Thr-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂H-pMel-Gln-Trp-Ala-Val-Gly-phe-Leu-Met-NH₂Boc-mMel-Gln-Trp-Ala-Val-Gly-His(Dnp)-Leu-Met-NH₂H-mMel-Gln-Trp-Ala-Val-Gly-His(Dnp)-Leu-Met-NH₂Boc-mMel-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂H-mMel-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂Boc-mMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂H-mMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂H-mMel-Leu-Gly-Thr-Gln-Trp-Ala-Val-Gly-Leu-NH₂H-pMel-Leu-Gly-Thr-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂H-pMel-Gln-Trp-Ala-Val-ala-His-Leu-Met-NH₂H-pMel-Asn-Gln-Trp-Ala-Val-Gly-Leu-Nle-NH₂H-pMel-Asn-Gln-Trp-Ala-Val-Gly-Leu-NH(CH₂)₄CH₃H-pMel-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂H-pMel-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂H-pMel-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-ala-Leu-Nle-NH₂H-pMel-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-ala-Leu-NH(CH₂)₂C₆H₅H-Glp-Arg-Leu-Gly-pMel-Asn-Gln-Trp-Ala-Val-Gly-Leu-Nle-NH₂H-Leu-Gly-pMel-Gln-Trp-Ala-Val-Gly-phe-Leu-Nle-NH₂H-Leu-Gly-pMel-Gln-Trp-Ala-Val-Gly-ala-Leu-Nle-NH₂H-pMel-Asn-Gln-Trp-Ala-Val-Gly-Leu-Leu-NH-NH₂Boc-pMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂H-pMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂Boc-Lys(Boc)-Gly-pMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂H-Lys-Gly-pMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂

Ac-Lys(Boc)-Gly-pMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂

Ac-Lys-Gly-pMel-Gln-Trp-Ala-Val-Gly-Leu-Met-NH₂

Boc-pMel-Leu-Gly-Thr-Gln-Trp-Ala-Val-His(Dnp)-Leu-NH(CH₂)₄CH₃

H-pMel-Leu-Gly-Thr-Gln-Trp-Ala-Val-His(Dnp)-Leu-NH(CH₂)₄CH₃

Boc-pMel-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-ala-Leu-Nle-NH₂ or

H-pMel-Gln-Arg-Leu-Gly-Asn-Glu-Trp-Ala-Val-ala-Leu-Nle-NH₂

3. A pharmaceutical composition comprising a peptide according to claim 1 or claim 2 or a pharmaceutically acceptable salt of such a peptide in admixture with a pharmaceutically acceptable diluent or carrier.

4. A process for the preparation of a peptide according to claim 1, the process comprising condensing amino acids and/or amino acid derivatives in the desired sequence and/or peptide fragments containing these amino acids or their derivatives in the desired sequence to give the desired peptide, either an end carboxylic acid group or an end amino group being activated for the peptide linkage and the remaining groups being protected, and optionally deprotecting the resultant peptide and/or converting the resultant peptide into a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No PCT/EP 89/00842

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC IPC ⁵ : C 07 K 7/06, C 07 K 7/08, A 61 K 37/02		
II. FIELDS SEARCHED		
Classification System IPC ⁵	Minimum Documentation Searched ⁷ Classification Symbols C 07 K, A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	FR, A, 2100975 (SOCIETA FARMACEUTICI ITALIA) 24 March 1972, see the whole document --	1, 2, 3
Y	Chemical Abstracts, vol. 110, 1989 (Columbus, Ohio, US), J. Hepp et al.: "Melfhalan analog of the dynorphin-(1-7)-heptapeptide", page 761, abstract no. 95784k, & F.E.C.S. Int. Conf. Chem. Biotechnol. Biol. Act. Nat. Prod., (Proc.), 3rd 1985, see abstract --	1, 3
Y	Chemical Abstracts, vol. 109, 1988, (Columbus, Ohio, US), J. Hepp et al.: "Synthesis of novel opioid peptides possessing an alkylating effect and investigation of their coupling to receptors", page 86, abstract no. 48561e, & Kem. Kozl. 1986, 65(1), 34-43, see abstract -- ./.	1, 3
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents: 10</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 3rd October 1989		Date of Mailing of this International Search Report - 3. 11. 89
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer T.K. WILLIS

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	US, A, 4331661 (MARKI) 25 May 1982, see the whole document --	1,3
A	Chemical Abstracts, vol. 109, 1988, (Columbus, Ohio, US), Ye.N. Shkodinskaya et al.: "Alkylating derivatives of 2-amino-2-deoxysaccharides and 1-methylamino-1-deoxypolyols (synthesis and experimental study)", page 728, abstract no. 55184n, Vopr. Onkol. 1987, 33(11), 48-53, see abstract --	1,3
P,A	Chemical Abstracts, vol. 108, 1988, (Columbus, Ohio, US), N.D. Lagova et al.: "The use of peptide hormone melanostatin and its analogs for synthesis of new antitumor compounds", page 101, abstract no. 180442a, & Vopr. Onko. 1988, 34(1), 73-9, see abstract --	1,3
A	US, A, 4207311 (BROWN) 10 June 1980, see the whole document ----	1,3

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 8900842

SA 29869

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 25/10/89. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A- 2100975	24-03-72	CH-A- 565140	15-08-75
		DE-A, B, C 2137971	03-02-72
		GB-A- 1309728	14-03-73
		US-A- 3792032	12-02-74
US-A- 4331661	25-05-82	None	
US-A- 4207311	10-06-80	None	